Although anti-PD-1 blockade, alone or in combination with chemotherapy or other ICIs, has been used in CRC, only some patients showed clinical advantage, and the mechanisms that underlying PD-1 resistance are still under investigation [3]. This evidence concerns the gene PDCD1 and colorectal carcinoma.